The BCL2-specific BH3 mimetic, venetoclax, is transforming blood cancer treatment, garnering FDA approvals in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML; refs. 3–9). This evidence concerns the gene BCL2 and acute myeloid leukemia.